Encouraging patients to participate in AML trials
Despite recent approvals of drugs targeting acute myeloid leukemia (AML), overall survival and complete remission rates remain suboptimal. In this interview, Eytan Stein, MD, from the Memorial Sloan K...
Author: VJOncology
Added: 05/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 25, 2018 Category: Cancer & Oncology Source Type: podcasts
Combining existing drugs for the creation of novel AML therapies
Gail Roboz, MD, from the Weill Medical College of Cornell University, New York City, NY, explores exciting next-generation agents for the treatment of acute myeloid leukemia (AML), such as guadecitabi...
Author: VJOncology
Added: 05/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 25, 2018 Category: Cancer & Oncology Source Type: podcasts
The challenges of choosing the right target antigen in AML compared to ALL
Treatment outcomes for acute myeloid leukemia (AML) patients treated with immunotherapy have significantly lagged behind those achieved for acute lymphoblastic leukemia (ALL), and this is due to the f...
Author: VJOncology
Added: 05/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 25, 2018 Category: Cancer & Oncology Source Type: podcasts
Primary and secondary resistance in AML
Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the mechanisms of resistance to targeted therapies such as enasidenib and ivosidenib in acute myeloid leukemia...
Author: VJOncology
Added: 05/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 25, 2018 Category: Cancer & Oncology Source Type: podcasts
Managing relapse in AML: the role of MRD
Patients suffering from acute myeloid leukemia (AML) who have achieved complete remission are still at risk of relapse. Assessing blood counts or examining the morphology of the bone marrow is not suf...
Author: VJOncology
Added: 05/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 25, 2018 Category: Cancer & Oncology Source Type: podcasts
Managing AML in elderly patients
Traditionally, the standard therapy for the management of acute myeloid leukemia (AML) in elderly patients has been low-dose cytarabine, but hypomethylating agents (HMAs) have quickly become the backb...
Author: VJOncology
Added: 05/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 25, 2018 Category: Cancer & Oncology Source Type: podcasts
Toxicity profiles of IDH inhibitors: are they as intimidating as they seem?
The side effects of isocitrate dehydrogenase (IDH) inhibitors for the treatment of acute myeloid leukemia (AML) include gastrointestinal toxicity, leukocytosis, differentiation syndrome and QT prolong...
Author: VJOncology
Added: 05/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 25, 2018 Category: Cancer & Oncology Source Type: podcasts
Immunotherapies for the treatment of AML
Gemtuzumab ozogamicin is a monoclonal antibody drug for the treatment of acute myeloid leukemia (AML). This drug uses a different strategy to classical chemotherapeutic agents, and the development of ...
Author: VJOncology
Added: 05/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 25, 2018 Category: Cancer & Oncology Source Type: podcasts
The complications of treating elderly patients with AML
The average age of people suffering from acute myeloid leukemia (AML) is around 60 to 70 years, and there are many issues surrounding the use of chemotherapy drugs in this population. In this intervie...
Author: VJOncology
Added: 05/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 25, 2018 Category: Cancer & Oncology Source Type: podcasts
MRD detection techniques in AML: pros and cons
Minimal residual disease (MRD) is a highly important prognostic indicator used to determine treatment efficacy in acute myeloid leukemia (AML) patients. Here, Chrisoph Rllig, MD, from the University ...
Author: VJOncology
Added: 05/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 25, 2018 Category: Cancer & Oncology Source Type: podcasts
Applying the right therapies to the right AML patient population
Chrisoph Rllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, discusses how his team is carrying out treatment optimization trials to match established acute myeloid leukemia ...
Author: VJOncology
Added: 05/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 24, 2018 Category: Cancer & Oncology Source Type: podcasts
The CAR T-cell therapy race
Unlike childhood acute lymphoblastic leukemia (ALL), there are currently no approved CAR T-cell products for the treatment of adult ALL; here, Noelle Frey, MD, from the University of Pennsylvania, Phi...
Author: VJOncology
Added: 05/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 24, 2018 Category: Cancer & Oncology Source Type: podcasts
CAR T-cell therapy and ALL: the current landscape
CAR T-cell therapy has proven effective in delivering high response rates in relapsed acute lymphoblastic leukemia (ALL) patients, but what can be done to move the field forward? Here, Noelle Frey, MD...
Author: VJOncology
Added: 05/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Combination therapy for the treatment of AML
Chrisoph Rllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, explains how the lack of novel drugs for the treatment of acute myeloid leukemia (AML) in the past 50 years has l...
Author: VJOncology
Added: 05/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Increasing the effectiveness of ALL therapies
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Charles Mullighan, MBBS (Hons), MSc, MD, from St. Jude Childrens Research Ho...
Author: VJOncology
Added: 05/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 18, 2018 Category: Cancer & Oncology Source Type: podcasts
